Bioventus Q3 2026: Sixth Straight EPS Beat, but Revenue Misses and Guidance Cut
As seen on the 24/7 Wall St. homepage on November 2, 2026.
Management trimmed full-year net sales guidance to $590 million to $595 million even as EPS beat for a sixth straight quarter, with revenue missing expectations. The review of strategic alternatives, triggered by an unsolicited acquisition proposal, stays open.
Continue ReadingShow less
Bioventus beat EPS expectations for a sixth straight quarter, but net sales of $142.44 million missed expectations even with revenue up 2.7% year over year.
Pain Treatments grew 6.2% on demand for hyaluronic acid therapies including Durolane, plus higher PRP and peripheral nerve stimulation volumes. Restorative Therapies declined, U.S. revenue barely moved, and international revenue expanded on Durolane and Ultrasonics.
Sponsored
Management trimmed full-year net sales guidance to $590 million to $595 million while reaffirming its adjusted EPS range. The cut signals the top-line shortfall extends beyond one quarter, adding caution for investors tracking the full-year setup.
The quarter carried $3.63 million in costs tied to the review of strategic alternatives, a process that began after an unsolicited acquisition proposal. CEO Rob Claypoole said the company continues to explore all opportunities to maximize shareholder value. That open review means a transaction announcement or rejection lands at any time and moves the stock.
Mentioned: BVS